Alto Neuroscience Secures U.S. Patent No. 12,521,374
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 14 2026
0mins
Alto Neuroscience announced the issuance of U.S. Patent Number 12,521,374 covering methods of treating depression with ALTO-207, a combination of pramipexole and ondansetron. The patent protects an aspect of ALTO-207 - the use of ondansetron to mitigate pramipexole-related side effects so that patients can achieve the higher dose levels needed to realize the antidepressant benefits of pramipexole.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on ANRO
Wall Street analysts forecast ANRO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ANRO is 32.86 USD with a low forecast of 16.00 USD and a high forecast of 50.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
9 Buy
0 Hold
0 Sell
Strong Buy
Current: 15.330
Low
16.00
Averages
32.86
High
50.00
Current: 15.330
Low
16.00
Averages
32.86
High
50.00
About ANRO
Alto Neuroscience, Inc. is a clinical-stage biopharmaceutical company focused on redefining psychiatry by leveraging neurobiology to develop personalized and effective treatment options. The Company's Precision Psychiatry Platform measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to identify which patients are likely to respond to its product candidates. Its clinical-stage pipeline includes drug candidates in bipolar depression, major depressive disorder, treatment resistant depression (TRD), and schizophrenia, and other mental health conditions. Its product candidates include ALTO-100, ALTO-300, ALTO-207, ALTO-203, ALTO-101, ALTO-202, and ALTO-208. ALTO-100 is a first-in-class, oral small molecule believed to work through enhancing neural plasticity in the hippocampus, a brain region important for both cognition and mood. ALTO-203 is an oral small molecule histamine H3 receptor inverse agonist.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Healthcare Stocks Surge in After-Hours Trading
- Acumen Pharmaceuticals Surge: Acumen Pharmaceuticals, Inc. (ABOS) advanced 8.09% in after-hours trading to close at $2.94, adding $0.22, indicating strong investor confidence in its growth prospects.
- Fulgent Genetics Rise: Fulgent Genetics, Inc. (FLGT) rose 5.98% to $28.90 in after-hours trading, gaining $1.63, reflecting market optimism regarding its business outlook.
- Fractyl Health Growth: Fractyl Health, Inc. (GUTS) climbed 5.19% to $2.23 after hours, up $0.11, suggesting that its potential in the biotech sector is being recognized by the market.
- Coeptis Therapeutics Increase: Coeptis Therapeutics Holdings, Inc. (COEP) added 4.14% to finish at $13.85, gaining $0.55 in after-hours trading, demonstrating investor support for its strategic direction.
Continue Reading
Alto Neuroscience and Others Under Investigation for Shareholder Claims
- Shareholder Lawsuit Investigation: Johnson Fistel, PLLP is investigating shareholder claims against Alto Neuroscience (NYSE: ANRO) and others, alleging breaches of fiduciary duty that could lead to corporate governance reforms and return of funds.
- False Statements Allegations: Alto Neuroscience is accused of making false statements regarding the efficacy of its lead drug ALTO-100, resulting in investor losses when the truth was revealed, negatively impacting the company's reputation and stock price.
- Anticompetitive Pricing Practices: Atkore Inc. (NYSE: ATKR) faces a securities class action lawsuit alleging executives failed to disclose anticompetitive pricing practices related to PVC pipe products, which may lead to legal risks and diminished shareholder trust.
- Safety Risks Concealment: Fly-E Group (NASDAQ: FLYE) is accused of downplaying safety risks associated with its lithium battery technology in electric mobility products, leading to a stock price decline and harming investor interests, affecting the company's future growth prospects.
Continue Reading